TechnologyPicnicHealth Launches New Service Bringing Observational Clinical Trials to...

PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm

-

Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted at observational research trials to enable trial sponsors to conduct research without a physical site.
These in-house providers can complete virtual visits with study subjects, perform health evaluations, order diagnostics, and report AEs, as stated in a release. This virtual infrastructure is designed to minimize the difficulties inherent in observational research and make it more comfortable for patients.

Built into PicnicHealth’s life sciences platform, Virtual Site can accommodate fully remote trials, as well as trials done in vulnerable populations, which in turn means that more trials can be done. The company believes that this will make the research process easier, increase patient uptake and response, and give diversity to samples. In addition, another anticipated advantage of the virtual system is the faster collection of data.
PicnicHealth’s main technology is data integration from medical records and their data representation. In the context of Virtual Site, this technology enables investigators to collect clinical outcomes that may not be recorded in actual clinical practice. This in a way aims to enhance the information acquired during clinical trials examinations and in this case makes the data more affluent.

In the previous year, PicnicHealth advanced greatly by sourcing real-world data on cancer patients in collaboration with AstraZeneca and buying AllStripes, an imperial rare disease data company. These steps have placed PicnicHealth in the real-world evidence and data collection domain and have turned Virtual Site into the company’s new key in redefining clinical research.

Latest news

BioNTech Agrees to $205 Million FDA Voucher Purchase for Oncology Pipeline

BioNTech has agreed to pay $205 million to acquire an FDA priority review voucher (PRV) from Scholar Rock, securing...

The Science Behind Bispecific Antibodies and Their Therapeutic Potential

Executive Summary Bispecific antibodies are an increasingly important class of engineered biologic medicines designed to recognize two distinct molecular targets...

Top 10 Emerging Technologies in Microbial Biotechnology

Executive Summary Microbial biotechnology is advancing as new technologies expand the ability to engineer, understand, and utilize microorganisms for industrial,...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you